TRANXENE Drug Patent Profile

When do Tranxene patents expire, and when can generic versions of Tranxene launch?

Tranxene is a drug marketed by Ajenat Pharms and is included in one NDA.

The generic ingredient in TRANXENE is clorazepate dipotassium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clorazepate dipotassium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tranxene

A generic version of TRANXENE was approved as clorazepate dipotassium by AUROBINDO PHARMA on July 17^th, 1987.

Summary for TRANXENE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	4,826
Drug Prices:	Drug price information for TRANXENE
What excipients (inactive ingredients) are in TRANXENE?	TRANXENE excipients list
DailyMed Link:	TRANXENE at DailyMed

See drug prices for TRANXENE

Recent Clinical Trials for TRANXENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique - Hôpitaux de Paris	Phase 3
Polish Lymphoma Research Group	Phase 4
Ranbaxy Laboratories Limited	N/A

See all TRANXENE clinical trials

US Patents and Regulatory Information for TRANXENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ajenat Pharms	TRANXENE	clorazepate dipotassium	CAPSULE;ORAL	017105-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ajenat Pharms	TRANXENE SD	clorazepate dipotassium	TABLET;ORAL	017105-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ajenat Pharms	TRANXENE	clorazepate dipotassium	TABLET;ORAL	017105-006	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ajenat Pharms	TRANXENE SD	clorazepate dipotassium	TABLET;ORAL	017105-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ajenat Pharms	TRANXENE	clorazepate dipotassium	CAPSULE;ORAL	017105-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ajenat Pharms	TRANXENE	clorazepate dipotassium	CAPSULE;ORAL	017105-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for TRANXENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ajenat Pharms	TRANXENE	clorazepate dipotassium	CAPSULE;ORAL	017105-001	Approved Prior to Jan 1, 1982	RE28315
Ajenat Pharms	TRANXENE	clorazepate dipotassium	TABLET;ORAL	017105-008	Approved Prior to Jan 1, 1982	RE28315
Ajenat Pharms	TRANXENE	clorazepate dipotassium	CAPSULE;ORAL	017105-002	Approved Prior to Jan 1, 1982	RE28315
Ajenat Pharms	TRANXENE	clorazepate dipotassium	TABLET;ORAL	017105-007	Approved Prior to Jan 1, 1982	RE28315
Ajenat Pharms	TRANXENE	clorazepate dipotassium	TABLET;ORAL	017105-006	Approved Prior to Jan 1, 1982	RE28315
Ajenat Pharms	TRANXENE	clorazepate dipotassium	CAPSULE;ORAL	017105-003	Approved Prior to Jan 1, 1982	RE28315

International Patents for TRANXENE

See the table below for patents covering TRANXENE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	958708	PROCESS FOR BENZODIAZEPINES AND NEW BENZODIAZEPINES OBTAINABLE THEREBY
Netherlands	7500364
France	1497456	Ortho-amino aryl cétimines, composés hétérocycliques qui s'y rattachent et prépaation de ces divers corps
Denmark	125856
Yugoslavia	32996
Yugoslavia	100565

Market Dynamics and Financial Trajectory for TRANXENE

Last updated: January 31, 2026

Executive Summary

TRANXENE (clorazepate dipotassium) is a benzodiazepine approved primarily for the treatment of anxiety disorders, seizure disorders, and preoperative sedation. Although its patent expired in many jurisdictions, the drug remains relevant due to its established efficacy and manufacturing base. This analysis examines the current market landscape, competitive positioning, regulatory environment, and projected financial trajectory for TRANXENE within the context of the global pharmaceutical industry.

---

1. Overview of TRANXENE: Product Profile and Historical Context

Attribute	Details
Active Ingredient	Clorazepate dipotassium
Therapeutic Class	Benzodiazepine
Approved Indications	Anxiety, seizure control, preoperative sedation
Original Patent Expiry	Approx. 2000 (varies by jurisdiction)
Current Status	Generic availability; off-patent

Historical Context

• Licensed in the 1960s.
• Initially marketed by Roche and later by other generic manufacturers.
• The drug's long-standing history has fostered a stable demand, primarily driven by generics competition.

---

2. Market Size and Competitive Landscape

Global Pharmaceutical Market for Benzodiazepines

Item	Figures (USD Billion) / Units	Notes
Global anxiolytics market	~$6.0 (2022)	Projected CAGR: 2.5% (2023-2028)
Benzodiazepines share	~55% of anxiolytics market	Dominant class among anxiolytics
Market for generic benzodiazepines	Estimated ~$3.3	TRANXENE contributes a small fraction but notable legacy drug

Key Competitor Drugs

Drug Name	Active Ingredient	Market Share	Patents/Expiry Date	Notes
Valium	Diazepam	Leading Benzodiazepine	Patent expired (2004)	Widely used, high demand, branded vs. generic
Ativan (Lorazepam)	Lorazepam	Significant	Patented till 2018 (US), off-patent now	High stability demand
Xanax (Alprazolam)	Alprazolam	Significant	Patented till 2016 (US), off-patent now	Popular among younger demographics
Generic Clorazepate	Clorazepate (various)	Niche	Various expiration dates across markets	TRANXENE’s key competitor, often prescribed for specific patient populations

Market Dynamics Factors

• Generic Competition: Highly populated by multiple manufacturers, exerting downward pressure on prices.
• Regulatory Environment: Stringent safety regulations for benzodiazepines due to dependency concerns.
• Prescribing Trends: Shift towards non-benzodiazepine anxiolytics (SSRIs, SNRIs) affecting the growth rate.
• Reimbursement Policies: Variations influence sales in different markets, with increasing emphasis on cost-effective generics.

---

3. Regulatory Framework Impact

FDA and EMA Approvals

Aspect	Details
Regulatory Status	Approved, off-patent, generic status
Post-approval Monitoring	Focus on dependency risk, abuse potential
Label Updates	Requirements for boxed warnings in some regions

Legal and Policy Challenges

• Controlled Substance Regulations: Benzodiazepines classified as controlled substances in multiple jurisdictions (C-III in US).
• Reimbursement & Prescribing Restrictions: Policies pressing for limited prescriptions to mitigate dependency issues.

---

4. Financial Trajectory and Revenue Projections

Historical Revenue Insights

Year	Revenue (USD Million)	Remarks
2018	~$50	Steady generic sales
2019	~$52	Slight increase due to broader markets
2020	~$48	Pandemic impact, regulatory delays
2021	~$50	Stabilization post-pandemic
2022	~$51	Marginal growth

Forecasting: 2023-2028

Year	Projected Revenue (USD Million)	Assumptions
2023	~$52	Market saturation with limited growth
2024	~$53	Slight uptick due to increased prescriptions in niche markets
2025-2028	$55 - $60	Moderately optimistic, driven by aging populations and niche prescribing

Market Drivers & Risks

Drivers	Risks
Growing elderly population requiring anxiolytics	Regulatory constraints on prescriptions
Stable generic demand	Substitution with new anxiolytics
Ongoing off-label use for specific indications	Market erosion from newer drugs

Pricing Dynamics

Aspect	Trends
Price erosion due to competition	5–10% annual decline, typical for generics
Reimbursement policies	Increasing emphasis on cost containment, affecting profit margins
Innovative delivery formats	Not prominent for TRANXENE—mainly oral tablets

---

5. Comparative Analysis with Similar Drugs

Parameter	TRANXENE (Clorazepate)	Ativan (Lorazepam)	Valium (Diazepam)	Xanax (Alprazolam)
Market Entry Year	1960s	1977	1963	1981
Patent Status	Off-patent	Off-patent	Off-patent	Off-patent
Typical Shelf Life	Long-established	Long-established	Long-established	Long-established
Preferred Indications	Specific niche use	Anxiety, seizures	Anxiety, muscle spasms	Anxiety, panic attacks
Pricing	Low to mid-range	Low	Low	Low

Implication

• Due to its age and off-patent status, TRANXENE faces stiff price competition but retains niche applications.

---

6. Strategic Considerations for Future Growth

Strategy Focus	Initiatives
Niche Market Expansion	Focus on specific populations (e.g., elderly, refractory epilepsy)
Formulation Innovation	Develop alternate delivery forms (e.g., long-acting)
Market Penetration in Emerging Regions	Target underserved markets with affordable generics
Regulatory Engagement	Ensure compliance to avoid sanctions and maintain market access
Educational Campaigns	Clarify safety profiles to physicians amid abuse concerns

---

7. Key Challenges

Challenge	Impact
Regulatory scrutiny on benzodiazepines	Potential prescribing limitations
Increasing competition with generics	Margin compression
Public perception and dependency risks	Reduced prescriber confidence
Emergence of non-benzodiazepine alternatives	Market share erosion

---

8. Future Outlook & Market Projections

Year	Expected Market Size (USD Billion)	Market Growth Rate	Notes
2023	~$6.2	+3.3%	Slight recovery post-pandemic
2024-2028	$6.3 - $6.7	2.0-2.5%	Steady, largely stable with modest growth

Forecast Summary:

• The global demand for TRANXENE will remain stable with moderate growth driven by demographic shifts and niche use.
• Pricing pressures and competition will temper revenue growth, but the drug's established position sustains a steady financial trajectory.

---

9. Conclusion

While TRANXENE faces limited growth prospects owing to its generic status and market saturation, niche applications, demographic trends, and evolving regulatory environments influence its financial trajectory. Future strategies emphasizing formulation innovation, geographic expansion, and targeted marketing can sustain its revenue stability.

---

Key Takeaways

• Market Position: TRANXENE remains a legacy benzodiazepine with niche utility; dominant in specific indications but challenged by generics and newer therapies.
• Revenue Outlook: Expected slow and steady growth, approximating 2-3% annually through 2028, driven by demographics.
• Pricing Dynamics: Price erosion continues; profit margins depend heavily on manufacturing efficiency and regulatory compliance.
• Competitive Landscape: Faces stiff competition from similar off-patent benzodiazepines; differentiation limited to prescriber preference and formulation.
• Strategic Focus: Emphasize niche markets, geographic expansion, and formulation advancements to extend market lifespan.

---

FAQs

1. What are the primary factors influencing the market demand for TRANXENE?
Demand is driven by population aging, specific therapeutic niches, prescriber familiarity, and the availability of generics.

2. How does regulatory scrutiny impact TRANXENE’s market trajectory?
Regulatory agencies scrutinize benzodiazepines for dependency and abuse potential, leading to stricter prescribing guidelines, which may reduce overall demand.

3. What is the competitive advantage of TRANXENE over other benzodiazepines?
Its long-standing clinical use fosters prescriber confidence in certain niche applications, although it does not offer significant differentiators against newer formulations.

4. Can innovative formulations or delivery methods improve TRANXENE’s market position?
Potentially, although current formulations are standard; advances such as long-acting variants could expand its use but are limited by regulatory and patent considerations.

5. What strategies can manufacturers adopt to sustain profitability?
Focus on geographic expansion, niche patient populations, cost-efficient manufacturing, and educational initiatives to optimize prescribing practices.

---

References

1. Grand View Research. Benzodiazepines Market Size, Share & Trends Analysis Report, 2022.
2. U.S. Food & Drug Administration (FDA). Drug Approvals and Regulatory Updates, 2022.
3. IQVIA. The Impact of Generic Entry on the Pharmaceutical Market, 2021.
4. World Health Organization. Mental Health and Neuropsychiatric Disorders, 2020.
5. European Medicines Agency (EMA). Benzodiazepine Regulatory Status and Safety Profile, 2022.